Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DARANIDE vs AZOPT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Edema due to congestive heart failure,Drug-induced edema,Glaucoma (adjunctive therapy)
Open-angle glaucoma,Ocular hypertension
50 mg orally once or twice daily; maximum 100 mg/day.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 m L/min).
Not extensively metabolized; excreted unchanged in urine.
Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion.
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
~90% bound, primarily to albumin.
Approximately 33% bound to plasma proteins (mainly albumin).
0.2-0.3 L/kg. Clinical meaning: Confined primarily to extracellular fluid; low Vd indicates minimal tissue distribution.
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid.
Oral: 75-85% (tablet).
Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption.
GFR 10-50 m L/min: 50 mg every 12-24 hours; GFR <10 m L/min: 50 mg every 24-48 hours; not effective if GFR <10 m L/min.
No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential metabolite accumulation.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: use not recommended.
No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Not established; use not recommended in children.
Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established.
Start at 25 mg once daily; monitor renal function and electrolyte balance due to increased risk of adverse effects.
No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue.
None.
None
May cause drowsiness, confusion, or paresthesias,Monitor electrolytes and renal function,Can cause metabolic acidosis,Use caution in patients with hepatic impairment or cirrhosis
Sulfonamide allergy (cross-reactivity possible),Corneal endothelial damage (risk increased with low endothelial cell count),Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma),Contaminated dropper tip may cause ocular infections
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal or hepatic dysfunction,Hypokalemia,Hyponatremia,Metabolic acidosis,Adrenal insufficiency
Hypersensitivity to brinzolamide or any sulfonamides,Severe renal impairment (Cr Cl <30 m L/min) or hyperchloremic acidosis
No specific food interactions reported. However, maintain adequate hydration to reduce risk of kidney stones. Avoid excessive salt intake if edema is present. Grapefruit juice is not known to interact.
No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances.
Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of electrolyte disturbances and acidosis in neonate; avoid use unless benefit outweighs risk.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis.
Contraindicated in breastfeeding. Excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in infant (metabolic acidosis, electrolyte imbalance).
It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown.
No standard dose adjustments; increased renal clearance in pregnancy may lower drug levels, but empirical dose changes are not recommended due to risk of metabolic acidosis. Use lowest effective dose if unavoidable.
No specific dose adjustments recommended; however, due to potential for increased systemic absorption during pregnancy (increased blood volume and ocular changes), monitor intraocular pressure closely. Use the lowest effective dose. Pharmacokinetic changes: unknown; adjust based on clinical response.
DARANIDE (dichlorphenamide) is a carbonic anhydrase inhibitor used for chronic open-angle glaucoma and secondary glaucoma. Monitor for metabolic acidosis, especially in patients with renal impairment. Can cause hypokalemia; check serum potassium periodically. Avoid concurrent use with high-dose salicylates due to risk of metabolic acidosis and salicylate toxicity. May cause drowsiness or confusion; caution in elderly. Not a first-line agent; reserved for patients intolerant or unresponsive to other therapies.
AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use.
Take exactly as prescribed, usually 3-4 times daily with food to reduce GI upset.,May cause tingling or numbness in fingers, toes, or mouth; this is common and usually harmless.,Drink plenty of fluids to prevent kidney stones; report painful urination or blood in urine.,Avoid aspirin or high-dose salicylates; check with doctor before taking any OTC pain relievers.,Regular eye exams and blood tests (potassium, bicarbonate) are necessary.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Tell your doctor if you have kidney disease, liver disease, or electrolyte imbalance.,Notify your doctor if you experience weakness, weight loss, confusion, or rapid breathing.
Shake the bottle vigorously before each use.,Remove contact lenses before instilling and wait at least 15 minutes before reinserting.,Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.,Report any eye pain, redness, or vision changes to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DARANIDE vs AZOPT, answered by our medical review team.
DARANIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.. AZOPT is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DARANIDE and AZOPT depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DARANIDE is: 50 mg orally once or twice daily; maximum 100 mg/day.. The standard adult dose of AZOPT is: One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DARANIDE and AZOPT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DARANIDE is classified as Category C. Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of . AZOPT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in ra. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.